Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib with Gemcitabine and Cisplatin in Pancreatic Adenocarcinoma
NCT01585805Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2012
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of veliparib in pancreatic adenocarcinoma (PDAC), sponsored by National Cancer Institute. Started May 2012; status: active, not recruiting.
02
Drugs
veliparib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01585805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01585805.